Groups Warn Against Avastin Biosimilar Off-Label Use in Eyes
Biosimilars are finally starting to bring down the prices of their innovator products across a range of indications, research shows. The FDA often approves biosimilars across some or all of the innovator drug’s indications even if applicant companies have not conducted studies in those uses. But two professional societies have been pushing back against payers’ allowance of two Avastin (bevacizumab) biosimilars in untested ocular indications.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQviaREAD MORE